VivoSeq
Other

GAN

0

Pipeline Programs↗

0

Active Trials↗

6

Companies Involved↗

GAN is an early-stage landscape with 0 programs across 6 companies. The most active players are Gan and Lee Pharmaceuticals, USA, Roche, Amgen.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Gan and Lee Pharmaceuticals, USA

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalAmgen logo

Amgen

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

PreclinicalM

Marinus Pharmaceuticals

0 programs

PreclinicalP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

32

clinical trials

Completed25 · 78%
Withdrawn3 · 9%
Unknown status2 · 6%
Terminated1 · 3%
No longer available1 · 3%

Clinical Trials

Trial Activity

32 trials

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
Completed·GGan and Lee Pharmaceuticals, USA·Phase 3·NCT03371108·567 enrolled
Sphenopalatine Ganglion Blocks RCT
Completed·UUniversity of California, San Francisco·Phase 4·NCT03666663·10 enrolled
TCF7L2 Polymorphisms Influence on Glycemic Control in ICU Patients With Organ Failure
Completed·UUniversity Hospital, Lille·N/A·NCT03055169·994 enrolled
Temporary Celiac Ganglion Block as a Test Before Celiac Ganglion Resection for Dysautonomia-Related Bowel Dysmotility
Completed·JJohns Hopkins University·Phase 1·NCT04121338·15 enrolled
Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed Condition
Completed·—·Phase 1·NCT02296723·66 enrolled
Sphenopalatine Ganglion Block Study
Completed·MMontefiore Medical Center·Phase 1·NCT05707754·220 enrolled
Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan
Completed·HHermann Eye Center·N/A·NCT00121147·200 enrolled
Vogelxo(R) ABPM Study in Hypogandal Men
Completed·UUpsher-Smith Laboratories·Phase 4·NCT04558567·122 enrolled
Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1
Completed·UUniversity Medical Center Goettingen·Phase 1·NCT02054299·48 enrolled
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients
Completed·Roche logoRoche·Phase 1·NCT01656525·28 enrolled
Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition
Completed·—·Phase 1·NCT02297854·83 enrolled
Sphenopalatine Ganglion Block for Nasal Surery
Completed·—·N/A·NCT04168879·110 enrolled
Study of Prophylactic Vs Preemptive Valganciclovir
Completed·WWashington University School of Medicine·N/A·NCT00374686·120 enrolled
TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST
Completed·UUniversity of Florence·Phase 4·NCT02366975·143 enrolled
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Completed·Amgen logoAmgen·Phase 2·NCT01327612·12 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)